Systematic Analysis of the Global, Regional and National Burden of Cardiovascular Diseases from 1990 to 2017

Abstract

Background Previous studies on the burden of cardiovascular diseases (CVDs) were mainly based on limited data of the study period or area, or did not include detailed risk factor analysis. Objective To investigate up-to-date temporal and regional trends and risk factors of mortality and disability-adjusted life years (DALYs) attributed to CVDs by age, sex, and disease throughout the world. Methods Data for the disease burden of CVDs in 195 countries and territories from 1990 to 2017, including mortality, DALYs, age-standardized mortality rates, and age-standardized DALY rates, were estimated from the Global Burden of Disease Study 2017. Risk factors attributable to deaths and DALYs for CVDs were also estimated using the comparative risk assessment framework. Results The number of deaths from CVDs increased by 48.62%, from 11.94 (95% UI 11.78–12.18) million in 1990 to 17.79 (17.53–18.04) million in 2017. However, the age-standardized mortality rate decreased by an average of − 1.45% (− 1.72% to − 1.18%) annually. After fluctuation in the expected age-standardized mortality rate of CVDs in most of the socio-demographic index (SDI) scale, these rates decrease rapidly for SDI values of 0.7 and higher. In 2017, metabolic risks accounted for 73.48% of deaths and 73.25% of DALYs due to CVDs, behavioral factors accounted for 63.23% of deaths and 66.71% of attributable DALYs. Conclusion CVDs remain a major global health burden due to the increment in death numbers and DALYs. Aging and the main risk factors are the main drivers of mortality and health loss. More attention to main risk factors should be paid with supportive health policies.

Identification of Novel and Recurrent Variants in BTD, GBE1, AGL and ASL Genes in Families with Metabolic Disorders in Saudi Arabia

“…These disorders are caused by genetic mutations that affect the function of enzymes and other proteins involved in various metabolic pathways. Metabolic disorders are becoming increasingly prevalent across genetically diverse populations worldwide, and they pose an increasing economic burden on public health systems in both developing and developed countries [ 2 , 3 ]. The global rise in the incidence of metabolic diseases is linked to several factors, including changes in dietary patterns, sedentary lifestyles, aging populations, and genetic predisposition [ 3 , 4 ].…”

Relationship between chronic disease resource utilization and quality of life in coronary heart disease patients: A latent profile analysis

“…Cardiovascular disease (CVD) remains a major public health threat that profoundly affects healthcare systems worldwide (Wang et al, 2022). There were approximately 523 million patients with CVD and 179 million patients with coronary heart disease (CHD) worldwide in 2019 (Roth et al, 2020).…”

Biomarker‐Responsive Nanosystems for Chronic Disease Theranostics

“…[ 7 ] In addition, CVDs remain to be a major global health burden, with ≈17.8 million deaths reported in 2017, which is equivalent to approximately one‐third of all deaths worldwide. [ 8,9 ] Kidney diseases are also chronic with a high fatality rate (1.2 million deaths reported in 2017). [ 10,11 ] In view of this severe situation of chronic diseases, efficient and sensitive diagnostic and therapeutic technologies are urgently needed.…”